Table 1.

Baseline characteristic of included 13 trials for analysis

Study	Total patients	Treatment line	Histologies			Treatment regimens	Primary endpoint	Median follow-up (mo)	Jadad score
			Adenocarcinoma	Squamous	Others
Heymach et al25	108	First line	59	26	23	Vandetanib 300 mg qd po + PTX + CBP Placebo + PTX + CBP	PFS	NR	5
Natale et al27	168	Second line	98	38	32	Vandetanib 300 mg qd po gefitinib 250 mg qd po	PFS	NR	5
Reck et al29	1,043	First line	876	0	167	Bev 7.5 mg/kg + DDP + GEM Bev 15 mg/kg + DDP + GEM Placebo + DDP + GEM	PFS	NR	5
Herbst et al34	1,391	Second line	829	344	218	Vandetanib 100 mg qd po + Doc Placebo + Doc	PFS	12.8	5
Hoang et al26	546	First line	202	191	153	Thalidomide 200 mg qd + PTX + CBP + RT PTX + CBP + RT	OS	61.8	3
Scagliotti et al14	926	First line	534	223	169	Sorafenib 400 mg bid po + CBP + PTX Placebo + PTX + CBP	OS	NR	5
de Boer et al24	534	Second line	336	114	84	Vandetanib 100 mg qd po + pemetrexed Placebo + pemetrexed	PFS	NR	5
Herbst et al33	636	Second line	477	28	131	Bev 15 mg/kg + erlotinib Erlotinib 150 mg qd po	OS	19	3
Natale et al28	1,240	Second line	741	272	227	Vandetanib 300 mg qd po + erlotinib Placebo + erlotinib	PFS	NR	5
Scagliotti et al31	960	Second line	506	270	184	Sunitinib 17.5 mg qd po + erlotinib Placebo + erlotinib qd po	OS	21.3	5
Scagliotti et al32	1,090	First line	890	0	200	Motesanib 125 mg qd po + CBP + PTX Placebo + CBP + PTX	OS	11	5
Garon et al15	1,253	Second line	912	328	13	Ramucirumab 10 mg/kg + Doc Placebo + Doc	OS	9.5	5
Doebele et al23	140	First line	122	0	18	Ramucirumab + Pemetrexed + platinum Pemetrexed + platinum	PFS	NR	3

Abbreviations: PTX, paclitaxel; CBP, carboplatin; DDP, cisplatin; GEM, gemcitabine; Doc, docetaxel; RT, radiotherapy; Bev, bevacizumab; PFS, progression-free survival; OS, overall survival; NR, not reported.